• 1
    Barnes P.J., Chung K.F., Page C.P. (1998) Inflammatory mediators of asthma: an update. Pharmacol Rev;50:515596.
  • 2
    Salmon J.A., Higgs G.A. (1987) Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull;43:285296.
  • 3
    Gottlieb S. (2001) COX 2 inhibitors may increase risk of heart attack. BMJ (Clinical research);323:471.
  • 4
    Juni P., Reichenbach S., Egger M. (2005) COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ (Clinical research);330:13421343.
  • 5
    Holroyde M.C., Altounyan R.E., Cole M., Dixon M., Elliott E.V. (1981) Leukotrienes C and D induce bronchoconstriction in man. Agents Actions;11:573574.
  • 6
    Gimbrone M.A. Jr, Brock A.F., Schafer A.I. (1984) Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Investig;74:15521555.
  • 7
    Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J. (1980) Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature;286:264265.
  • 8
    Piper P.J. (1985) Leukotrienes: potent mediators of airway constriction. Int Arch Allergy Immunol;76(Suppl 1):4348.
  • 9
    Sampson A.P. (1996) The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy;26:9951004.
  • 10
    van Deventer S.J. (2002) Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut;50(Suppl 3):III47III53.
  • 11
    Brooks C.D., Summers J.B. (1996) Modulators of leukotriene biosynthesis and receptor activation. J Med Chem;39:26292654.
  • 12
    Ruzicka T., Simmet T., Peskar B.A., Braun-Falco O. (1984) Leukotrienes in skin of atopic dermatitis. Lancet;1:222223.
  • 13
    Wedi B., Kapp A. (2001) Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs;15:729743.
  • 14
    Sampson A.P., Thomas R.U., Costello J.F., Piper P.J. (1992) Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol;33:423430.
  • 15
    De Caterina R., Zampolli A. (2004) From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med;350:47.
  • 16
    Wenzel S.E., Kamada A.K. (1996) Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother;30:858864.
  • 17
    Kawasaki Y., Tanji M., Takano K., Fukuda Y., Isome M., Nozawa R., Suzuki H., Hosoya M. (2005) The leukotriene B4 receptor antagonist ONO-4057 inhibits mesangioproliferative changes in anti-Thy-1 nephritis. Nephrol Dial Transplant;20:26972703.
  • 18
    Uz T., Dimitrijevic N., Imbesi M., Manev H., Manev R. (2008) Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice. Neurosci Lett;436:269272.
  • 19
    Cho Y.S., Kim H.S., Kim C.H., Cheon H.G. (2006) Application of the ferrous oxidation-xylenol orange assay for the screening of 5-lipoxygenase inhibitors. Anal Biochem;351:6268.
  • 20
    Hofmann B., Barzen S., Rodl C.B., Kiehl A., Borig J., Zivkovic A., Stark H., Schneider G., Steinhilber D. (2011) A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors. J Med Chem;54:19431947.
  • 21
    Romano M., Chen X.S., Takahashi Y., Yamamoto S., Funk C.D., Serhan C.N. (1993) Lipoxin synthase activity of human platelet 12-lipoxygenase. The Biochemical journal 296 (Pt 1): 127133.
  • 22
    Waslidge N.B., Hayes D.J. (1995) A colorimetric method for the determination of lipoxygenase activity suitable for use in a high throughput assay format. Anal Biochem;231:354358.
  • 23
    Nie D., Krishnamoorthy S., Jin R., Tang K., Chen Y., Qiao Y., Zacharek A., Guo Y., Milanini J., Pages G., Honn K.V. (2006) Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. The Journal of biological chemistry;281:1860118609.
  • 24
    Shureiqi I., Wu Y., Chen D., Yang X.L., Guan B., Morris J.S., Yang P., Newman R.A., Broaddus R., Hamilton S.R., Lynch P. (2005) The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res;65:1148611492.
  • 25
    Deschamps J.D., Gautschi J.T., Whitman S., Johnson T.A., Gassner N.C., Crews P., Holman T.R. (2007) Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem;15:69006908.
  • 26
    Parker C.W., Aykent S. (1982) Calcium stimulation of the 5-lipoxygenase from RBL-1 cells. Biochem Biophys Res Commun;109:10111016.
  • 27
    Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol;78:206209.
  • 28
    Bursavich M.G., Parker D.P., Willardsen J.A., Gao Z.H., Davis T., Ostanin K., Robinson R., Peterson A., Cimbora D.M., Zhu J.F., Richards B. (2010) 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97). Bioorg Med Chem Lett;20:16771679.
  • 29
    Cho Y.S., Kim N.J., Suh J.H., Yoo S.E., Cheon H.G., Yi K.Y., Song J.S., Bae M.Y., Kim H.Y., Hwang S.H., Song J.H. (2008) Thiazole derivatives, preparation thereof and pharmaceutical compositions comprising the same. Patent KR10-820935.
  • 30
    Cho Y.S., Kim C.H., Surh J.H., Kang N.S., Yoo S.E., Cheon H.G. (2010) Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl-phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity. Pharmacology;86:6572.